| 2 h | 4 h | |||
| Triple vs TIO | Triple vs SFC | Triple vs TIO | Triple vs SFC | |
| Day 1 | ||||
| FEV1 | 0.05 (−0.02, 0.12); p = 0.093 | −0.01 (−0.08, 0.06); p = 0.792 | 0.06 (−0.01,0.13); p = 0.047 | 0.04 ( 0.03,0.11); p = 0.188 |
| FVC | 0.20 (0.05, 0.36); p = 0.004 | 0.09 (−0.07, 0.25); p = 0.206 | 0.22 (0.07,0.37); p = 0.002 | 0.20 (0.04,0.36): p = 0.005 |
| IC | 1.03 (0.97, 1.09); p = 0.345 | 1.04 (0.98, 1.11); p = 0.152 | 1.02 (0.96, 1.08); p = 0.472 | 1.05 (0.98, 1.12); p = 0.065 |
| RV | 0.99 (0.94, 1.03); p = 0.481 | 0.99 (0.94, 1.04); p = 0.604 | 0.92 (0.88, 0.97); p<0.001 | 0.95 (0.90, 1.009); p = 0.017 |
| TLC | 1.02 (1.00, 1.04); p = 0.068 | 1.01 (0.99, 1.03); p = 0.507 | 0.99 (0.98, 1.01); p = 0.451 | 1.00 (0.98, 1.02); p = 0.873 |
| Day 14 | ||||
| FEV1 | 0.20 (0.10, 0.30); p<0.001 | 0.09 (−0.003, 0.19); p = 0.029 | 0.25 (0.15, 0.35); P< 0.001 | 0.10 (0.002, 0.19); p = 0.023 |
| FVC | 0.30 (0.12, 0.48); p<0.001 | 0.21 (0.03, 0.39); p = 0.010 | 0.45 (0.27, 0.63); p<0.001 | 0.22 (0.04, 0.41); p = 0.007 |
| IC | 1.10 (1.04, 1.17); p<0.001 | 1.08 (1.02, 1.15); p = 0.004 | 1.15 (1.08, 1.22); p<0.001 | 1.10 (1.04, 1.17); p<0.001 |
| RV | 0.90 (0.85, 0.95); p<0.001 | 0.94 (0.89, 1.00); p = 0.022 | 0.91 (0.86, 0.96); p<0.001 | 0.96 (0.90, 1.02); p = 0.092 |
| TLC | 1.00 (0.98, 1.02); p = 0.706 | 1.01 (0.99, 1.03); p = 0.499 | 1.01 (0.99, 1.03); p = 0.191 | 1.01 (0.99, 1.03); p = 0.373 |
For FEV1, figures represent treatment differences with 97.5% CI and p values; for IC, RV and TLC, figures represent a treatment ratio with 97.5% CI and p value.
IC, Inspiratory capacity; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; SFC, salmeterol/fluticasone propionate combination; TIO, tiotropium; TLC, total lung capacity.